These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 2162506)

  • 1. A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractionated heparin.
    Anastassiades E; Ireland H; Flynn A; Lane DA; Curtis JR
    Nephrol Dial Transplant; 1990; 5(2):135-40. PubMed ID: 2162506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
    Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
    Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept.
    Leitienne P; Fouque D; Rigal D; Adeleine P; Trzeciak MC; Laville M
    Nephrol Dial Transplant; 2000 Oct; 15(10):1631-7. PubMed ID: 11007833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
    Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
    Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure.
    Lane DA; Flynn A; Ireland H; Anastassiades E; Curtis JR
    Haemostasis; 1986; 16 Suppl 2():38-47. PubMed ID: 3744134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
    Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
    Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin).
    Eichinger S; Wolzt M; Schneider B; Nieszpaur-Los M; Heinrichs H; Lechner K; Eichler HG; Kyrle PA
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):886-92. PubMed ID: 7600120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
    Andrassy K
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis.
    Ryan KE; Lane DA; Flynn A; Shepperd J; Ireland HA; Curtis JR
    Thromb Haemost; 1991 Sep; 66(3):277-82. PubMed ID: 1745997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
    Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
    Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical study on low-molecular weight heparin infusion as anticoagulation for nocturnal home haemodialysis.
    Wong SS; Lau WY; Ng ML; Chan SY; Chan SF; Chan PK; Wan CK; Cheng YL
    Nephrology (Carlton); 2018 Apr; 23(4):317-322. PubMed ID: 28052451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
    Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
    Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cross-over study of a new low molecular weight heparin (Logiparin) in hemodialysis.
    Koutsikos D; Fourtounas C; Kapetanaki A; Dalamanga A; Tzanatos H; Agroyannis B; Kopelias I; Bosiolis B; Rammos G; Bovoleti O; Sallum G; Darema M
    Int J Artif Organs; 1996 Aug; 19(8):467-71. PubMed ID: 8841845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis.
    Grau E; Sigüenza F; Maduell F; Linares M; Olaso MA; Martinez R; Caridad A
    Nephron; 1992; 62(1):13-7. PubMed ID: 1331831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
    Naumnik B; Borawski J; Myśliwiec M
    Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
    Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
    Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
    Nimmerfall K; Mischke R
    Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
    Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
    Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.